When most people talk about cannabinoids, they jump straight to CBD, THC, or maybe CBG. But the cannabis plant — and the world of synthetic cannabinoid chemistry — contains dozens of lesser-known compounds with genuinely fascinating biological profiles.
CBDD (cannabidiol dimethyl ether) is one of them. It doesn’t have the mainstream recognition of its parent molecule, CBD, but the research that does exist paints an interesting picture — particularly around inflammation, cardiovascular risk, and enzyme inhibition.
Here’s everything currently known about CBDD, written plainly.
What Is CBDD?
CBDD stands for cannabidiol-2′,6′-dimethyl ether (CAS# 1242-67-7). It is a chemical derivative of cannabidiol (CBD), structurally modified by replacing the two hydroxyl (–OH) groups on CBD’s resorcinol ring with methyl groups — hence the name “dimethyl ether.”
In nature, CBDD occurs as a trace component of the cannabis plant. It can also be produced synthetically in a laboratory setting, which is how most research-grade samples are obtained. Lab-grade CBDD is typically available at ≥98% purity as an analytical reference standard.
CAS Number: 1242-67-7
Parent compound: Cannabidiol (CBD)
Classification: Minor cannabinoid / synthetic CBD derivative
Psychoactive: No evidence of psychoactivity
CBDD vs. CBD: What’s the Difference?
CBDD is structurally very close to CBD — it shares the same backbone — but the methylation of its resorcinol hydroxyl groups changes its behavior meaningfully at the molecular level.
| Property | CBD | CBDD |
|---|---|---|
| Source | Major cannabis component | Trace cannabis component / synthetic |
| 15-LOX IC₅₀ | 2.56 μM | 0.28 μM (≈9× more potent) |
| Psychoactivity | None | None reported |
| Resorcinol OH groups | Free (–OH) | Methylated (–OCH₃) |
| Research volume | Extensive | Very limited |
| Consumer availability | Widely available | Research use only |
The key takeaway: CBDD is structurally derived from CBD, but the methylation makes it a significantly more potent inhibitor of at least one important enzyme — 15-lipoxygenase (15-LOX).
How CBDD Works in the Body
15-Lipoxygenase (15-LOX) Inhibition
The most well-documented mechanism of CBDD is its inhibition of the enzyme 15-lipoxygenase (15-LOX). This enzyme plays a major role in oxidizing low-density lipoprotein (LDL) — the so-called “bad cholesterol” — into oxidized LDL (ox-LDL), which is a primary driver of atherosclerosis (plaque buildup in the arteries).
Research shows that CBDD inhibits 15-LOX with an IC₅₀ of just 0.28 μM, making it roughly nine times more potent than CBD (IC₅₀ of 2.56 μM) in this specific role. Importantly, CBDD appears to be selective for 15-LOX rather than inhibiting other lipoxygenase enzymes broadly, which could be significant from a pharmacological precision standpoint.
Cytochrome P450 Enzyme Interactions
Like many cannabinoids, CBDD also interacts with the cytochrome P450 enzyme family, which is responsible for metabolizing a large percentage of pharmaceutical drugs in the body. Specifically:
- CYP2C19: CBDD inhibits this enzyme with an IC₅₀ of 14.8 μM
- CYP2B6: CBDD inhibits this enzyme with an IC₅₀ of 75.7 μM
These interactions are worth noting — particularly for anyone taking medications metabolized by CYP2C19 (such as certain antidepressants, antifungals, or proton pump inhibitors) — though CBDD is not currently available as a consumer supplement, making this primarily a research consideration for now.
LDL Oxidation Protection
In laboratory studies, CBDD has shown the ability to protect LDL particles from oxidative modification by both enzymatic (15-LOX) and non-enzymatic (copper ion-mediated) pathways. This dual protective effect against ox-LDL formation is one of the more compelling aspects of its cardiovascular research profile.
What the Research Says
Published research on CBDD is still limited, but a few key studies stand out:
2009 — Potent 15-LOX Inhibition Identified
A study published in Drug Metabolism and Disposition (Takeda et al.) was among the first to characterize CBDD as a highly potent and selective 15-lipoxygenase inhibitor, establishing its ICâ‚…â‚€ value and comparing it favorably to both CBD and THC in enzyme inhibition assays.
2011 — LDL Protection Demonstrated
Subsequent research demonstrated CBDD’s ability to protect against 15-LOX-mediated oxidation of cholesteryl linoleate — the major fatty acid esterified to cholesterol in LDL particles. At 5 μM, CBDD showed strong inhibitory effects on LDL oxidation, outperforming Δ9-THC in enzyme-specific protection.
2015 — Body Weight Effects in ApoE-Deficient Mice
A 2015 PubMed study examined CBDD’s effects on body weight in ApoE-deficient mice — a model used to study compromised lipid metabolism. Interestingly, CBDD increased body weight gain to a greater extent than vehicle-treated ApoE-deficient mice, a finding that contrasts with CBD’s known anorectic (appetite-suppressing) effects. This suggests CBDD and CBD may diverge meaningfully in their metabolic impacts.
Is CBDD Available as a Supplement?
Currently, CBDD is not available as a consumer supplement. It is sold exclusively as an analytical reference standard for laboratory and research use, typically at quantities of a few milligrams and high purity levels (≥98%).
Given how early-stage the research is, CBDD remains firmly in the domain of academic and pharmaceutical investigation. Whether it ever becomes a consumer product will depend on future clinical research, safety profiling, and regulatory review.
Frequently Asked Questions About CBDD
Is CBDD psychoactive?
There is no evidence that CBDD is psychoactive. Like its parent compound CBD, CBDD does not appear to interact with cannabinoid receptors (CB1/CB2) in a way that would produce intoxicating effects.
Is CBDD legal?
CBDD is not a scheduled substance in the United States, and it is not specifically listed under federal drug scheduling. However, as with all minor cannabinoids, legal status can vary by jurisdiction and is subject to change. It is currently only available for research purposes.
How does CBDD differ from CBD?
CBDD is a methylated derivative of CBD — two hydroxyl groups on CBD’s resorcinol ring are replaced with methyl groups. This structural change makes CBDD approximately nine times more potent as a 15-lipoxygenase inhibitor compared to CBD, while the two compounds appear to diverge in their metabolic and body weight effects as well.
Does CBDD occur naturally in cannabis?
Yes, but only in trace amounts. CBDD is considered a minor cannabinoid in the cannabis plant. Most research-grade CBDD is produced synthetically rather than extracted from plant material.
What is 15-lipoxygenase and why does it matter?
15-Lipoxygenase (15-LOX) is an enzyme that oxidizes fatty acids, including those within LDL (“bad cholesterol”) particles. When 15-LOX oxidizes LDL, it produces ox-LDL, which is a key driver of atherosclerosis — the buildup of arterial plaques associated with heart disease and stroke. Inhibiting 15-LOX is considered a potential strategy for cardiovascular risk reduction.
The Bottom Line
CBDD is one of many cannabinoids that exists at the edges of mainstream awareness — minor in occurrence, but potentially significant in effect. Its exceptional potency as a 15-LOX inhibitor, combined with its ability to protect LDL from oxidative modification, makes it an interesting compound for cardiovascular research.
That said, the research base is still very thin, all work so far has been done in cells or animals, and CBDD is not available to consumers. For now, it’s a compound worth keeping an eye on — a reminder that the cannabis plant (and its chemistry) almost certainly still holds surprises for researchers willing to look beyond the headline cannabinoids.
As with all cannabinoid content on this blog, nothing here constitutes medical advice. Always consult a qualified healthcare provider before making decisions about supplementation or treatment.
